成都康弘药业集团股份有限公司 关于公司收到药品注册证书的公告

Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd. has received the drug registration certificate for Mirabegron Extended-Release Tablets, which enhances the company's product pipeline and addresses overactive bladder symptoms in adults [1][2][3]. Group 1: Drug Information - Drug Name: Mirabegron Extended-Release Tablets - Dosage Form: Tablet - Specification: 50mg - Indication: Symptomatic treatment for adults with overactive bladder (OAB) characterized by urgency, frequency, and/or urge incontinence [1][2]. Group 2: Registration Details - Registration Classification: Chemical Drug Class 4 - Approval Number: National Drug Approval Code H20255960 - Approval Conclusion: The drug meets the requirements for registration as per the Drug Administration Law of the People's Republic of China [2]. Group 3: Impact on the Company - The approval of Mirabegron Extended-Release Tablets enriches the company's product pipeline, although the production and sales of pharmaceutical products may be influenced by national policies and market environment changes, leading to uncertainties [3].